Bristol-Myers Squibb (NY:BMY)

The most recent $0.60 Q dividend was declared September 10th for shareholders of record October 4th and is payable November 1st. There’s time to fetch this payout!

Current Report: Bristol-Meyers Squibb (BMY) ↗

September 16, 2024

Via Talk Markets

Merck Scores Two Key Victories With Keytruda In Women's Cancers ↗

September 15, 2024

The company also unveiled 10-year test results for Keytruda in advanced melanoma patients.

Via Investor's Business Daily

Bristol Myers Squibb Presents Landmark 10-Year Follow-Up Data from CheckMate -067 Which Showed Continued Durable Long-Term Survival Benefit with Opdivo® plus Yervoy® in Advanced Melanoma

September 15, 2024

These two stocks have had their issues in recent years, but both look like reliable long-term bets.

Market Whales and Their Recent Bets on BMY Options ↗

August 27, 2024

Via Benzinga

Got $200? 2 Healthcare Stocks to Buy and Hold Forever ↗

September 14, 2024

Biotechnology stocks and biotech exchange-traded funds ETFs once played a significant role in growth equity rallies, but today it seems like those days are in the past. Will an interest rate cut help...

Time To Invest And Or Trade In Bio-Tech Stocks? ↗

September 13, 2024

Via Talk Markets

Topics ETFs

Bristol Myers Squibb to Report Results for Third Quarter 2024 on October 31, 2024

September 12, 2024

Bristol Myers Squibb Announces Dividend

September 10, 2024

Bernie Sanders Says If You're Poor In America You'll Live 10-15 Years Less: 'Anybody Else See A Problem With That?' ↗

September 09, 2024

Via Benzinga

Enliven Therapeutics' Leukemia Candidate Could Challenge Pfizer, AstraZeneca In Broader Target Market: Analyst ↗

September 09, 2024

HC Wainwright initiated coverage on Enliven Therapeutics, noting its innovative small molecules for tumor treatments. HC Wainwright gave a Buy rating with a $37 price target, projecting significant...

Via Benzinga

Bristol Myers Squibb to Present Data at ESMO Demonstrating Ongoing Leadership in Immuno-Oncology and Progression of Assets from Its Differentiated Research Platforms

September 09, 2024

These dividend payers could more than double their payouts in the decade ahead.

2 Unstoppable Dividend Growth Stocks You Can Buy Now With $100 ↗

September 08, 2024

FDA faces inspection backlog with serious public health implications, as critical drug manufacturing plants remain unchecked.

FDA Battles Backlog of Drug Factory Inspections Since COVID-19 ↗

September 06, 2024

Via Benzinga

Bristol Myers Squibb Employees to Relay Nearly 3,000 Miles Cross-Country Aspiring to Raise Over $1 Million for the V Foundation for Cancer Research

September 06, 2024

Despite Medicare Negotiations, Americans May Still Have To Pay More For Prescription Drugs ↗

September 03, 2024

Despite Medicare's first-ever negotiated drug prices under the Inflation Reduction Act, U.S. costs remain significantly higher than those in other wealthy nations, with some prices still more than...

Via Benzinga

Topics Economy

2 Reasons Bristol Myers Squibb Stock Could Be a Bargain, Down 34% From Its All-Time High ↗

September 02, 2024

Rebounding growth could make shares of this leading drugmaker a big winner.

No stock is perfect, but quality businesses can stand the test of time in your portfolio.

2 No-Brainer Large-Cap Stocks to Buy With $500 Right Now ↗

September 01, 2024

Long-Term Follow-Up Data from Phase 3 Study of CAMZYOS® (mavacamten) Underscores Established Efficacy and Safety Profile in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)

September 01, 2024

Stock Market Rally Mixed; Dow Jones Hits High While Nvidia Tumbles On Earnings: Weekly Review ↗

August 30, 2024

The Dow Jones hit a new high while Nvidia led a Nasdaq retreat.

Via Investor's Business Daily

Topics Stocks

Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet ↗

August 30, 2024

The Benzinga Stock Whisper Index looks at five stocks seeing above average interest from investors during the week.

Via Benzinga

As Regulators Gear Up To Decide On Bristol Myers' Schizophrenia Treatment, Neurocrine Biosciences' Data Disappoints Investors ↗

August 28, 2024

Neurocrine Biosciences reports Phase 2 trial results for NBI-1117568 showing significant improvement in schizophrenia symptoms, with an 18.2-point reduction in PANSS scores at a 20 mg dose.

Via Benzinga

Kohl's Posts Upbeat Q2 Earnings, Joins Box, Waldencast, AeroVironment And Other Big Stocks Moving Higher On Wednesday ↗

August 28, 2024

Via Benzinga

Neurocrine Bio Dives As Schizophrenia Trial Results Lags Peers ↗

August 28, 2024

As new schizophrenia drugs move toward approval, Neurocrine Biosciences reports a subpar outcome for its phase 2 trial.

Via Investor's Business Daily

3 High-Yield Dividend Stocks With Payout Ratios Below 75% ↗

August 28, 2024

Unlock steady income and growth potential with these high-yield, low-risk dividend powerhouses.

These underappreciated dividend payers offer yields above 4% at recent prices.

2 Beaten-Down S&P 500 Dividend Stocks to Buy on the Dip and Hold Forever ↗

August 28, 2024

Regulators Expected To Approve Innovative Schizophrenia Treatment From Bristol Myers, Karuna ↗

Topics Stocks

August 27, 2024

Drug companies are investing in schizophrenia treatments as patients are desperate for a drug that has few side effects, Bloomberg reports.

Via Benzinga

Bristol Myers Squibb to Participate in Upcoming Investor Conferences

August 27, 2024

Bristol Myers Squibb to Present Data Across Cardiovascular Portfolio at the European Society of Cardiology Congress 2024

August 26, 2024